Please assess the completion status of the following clinical trial:

Trial Title: A Trial of Bardoxolone Methyl in Patients With CKD at Risk of Rapid Progression (MERLIN)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of CKD with screening eGFR (average of Screen A and Screen B eGFR values) ≥ 20 to \< 60 mL/min/1.73 m2~* Patient must meet at least one of the following criteria:~  1. UACR ≥ 300 mg/g; OR~ 2. eGFR decline at a rate of ≥ 4 mL/min/1.73 m2 in prior year; OR~ 3. Hematuria defined as \> 5-10 red blood cells (RBCs) per high power field (HPF, manual method), or documented history of positive urinary dipstick for blood in prior year, or macroscopic hematuria in prior 3 years;~* Systolic blood pressure ≤ 150 mmHg and diastolic blood pressure ≤ 90 mmHg at Screen A visit after a period of rest (≥ 5 minutes);~* Treatment with an angiotensin-converting enzyme inhibitor (ACEi) and/or an angiotensin II receptor blocker (ARB) at the maximally tolerated labeled daily dose for at least 6 weeks prior to the Screen A visit and with no anticipated changes to dose(s) during study participation.~* Able to swallow capsules -~Exclusion Criteria:~* Prior exposure to bardoxolone methyl;~* CKD secondary to or associated with any of the following:~  1. History of rapidly progressive glomerulonephritis (RPGN)~ 2. Glomerulonephritis requiring immunosuppression in the last 6 months prior to Screen A;~* Concomitant use of tolvaptan.~* Systemic immunosuppression for more than 2 weeks, cumulatively, within the 12 weeks prior to Day 1 or anticipated need for immunosuppression during the study;~* Patients currently taking a sodium/glucose cotransporter-2 inhibitor (SGLT2i), requiring dose adjustments within 12 weeks prior to Day 1 or if dose is anticipated to change during study participation;~* B-type natriuretic peptide (BNP) level \> 200 pg/mL at Screen A visit;~* Uncontrolled diabetes (HbA1c \> 11.0%) at Screen A visit;~* Serum albumin \< 3 g/dL at Screen A visit;~* Kidney or any other solid organ transplant recipient or a planned transplant during the study;~* Acute dialysis or acute kidney injury within 12 weeks prior to Screen A visit or during Screening;~* History of clinically significant cardiac disease;~* Systolic blood pressure \< 90 mmHg at Screen A visit after a period of rest;~* Body mass index \< 18.5 kg/m2 at the Screen A visit;~* History of malignancy within 5 years prior to Screen A visit, with the exception of localized skin or cervical carcinomas;~* Coronavirus disease 2019 (COVID-19) diagnosis within 3 months prior to Screen A or have ever required COVID-19 related hospitalization;~* Participation in other interventional clinical studies within 3 months (or if relevant 5 half-lives of that study medication, whichever is the longer) prior to Screen B;~* Unwilling to practice acceptable methods of birth control;~* Women who are pregnant or breastfeeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Bardoxolone methyl (Type: EXPERIMENTAL): Patients randomized to receive bardoxolone methyl capsules orally once daily for 12 weeks at a starting dose of 5 mg and titrated up to a maximal dose of 20 mg (participants with UACR less than or equal to 300 mg/g) or 30 mg (participants with UACR greater than 300 mg/g)~Patients will be scheduled to be assessed during treatment at Day 1, Weeks 1, 2, 4, 6, 8, and 12 and by telephone contact on Days 3, 10, 21, 31, 35, and 45. Patients will not receive any drug during a 5-week off-treatment period between Weeks 12 and 17. Patients will be assessed on Day 3 off-treatment (OT), Day 7 OT, Day 14 OT, Day 21 OT, Day 28 OT, and Day 35 OT. The OT day corresponds to days after last dose.~Patients will be assessed at and end-of-study (EOS) visit on Week 17.
- Placebo (Type: PLACEBO_COMPARATOR): Patients who received placebo, once-daily, orally, remained on placebo throughout the study duration of 12 weeks and followed the same titration to maintain the blind,~Patients will be scheduled to be assessed during treatment at Day 1, Weeks 1, 2, 4, 6, 8, and 12 and by telephone contact on Days 3, 10, 21, 31, 35, and 45. Patients will not receive any drug during a 5-week off-treatment period between Weeks 12 and 17. Patients will be assessed on Day 3 off-treatment (OT), Day 7 OT, Day 14 OT, Day 21 OT, Day 28 OT, and Day 35 OT. The OT day corresponds to days after last dose.~Patients will be assessed at and end-of-study (EOS) visit on Week 17.

Based on this trial design, predict the completion outcome and termination type (if applicable).